BIOGEN INC

Minor Lloyd’s recent Biogen stock sale is routine liquidity, not a warning—insider buying stays strong and analysts see continued upside.

Insider buying at Biogen signals executive confidence in the company’s outlook, with William A. Hawkins and peers adding shares after the Apellis merger.

Biogen insider buying signals cautious optimism amid Apellis deal – insider Sean Godbout’s recent trades suggest strategic confidence and potential price rebound.

Biogen CEO’s February trades show confidence, with a modest net purchase amid routine vesting—insider activity signals growth optimism, not market moves.

Biogen insider buy by Head of Development signals confidence before earnings; assess how it may boost stock and guide investor decisions.